{"result": "(\"entity\"<|>DÍAZ PÉREZ JA<|>PERSON<|>Díaz Pérez JA is an author referenced in the context of pheochromocytoma and paraganglioma in the manual of Endocrinology and Nutrition.)\n##\n(\"entity\"<|>CRESPO HERNÁNDEZ I<|>PERSON<|>Crespo Hernández I is an author referenced in the context of pheochromocytoma and paraganglioma in the manual of Endocrinology and Nutrition.)\n##\n(\"entity\"<|>FEOCROMOCITOMA<|>EVENT<|>Feochromocytoma is a type of tumor that secretes catecholamines and can be malignant, requiring specific diagnostic and therapeutic approaches.)\n##\n(\"entity\"<|>PARAGANGLIOMA<|>EVENT<|>Paraganglioma is a tumor similar to pheochromocytoma, often associated with a higher risk of malignancy and multiple lesions.)\n##\n(\"entity\"<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>ORGANIZATION<|>The Manual de Endocrinología y Nutrición is a reference book that provides guidelines and information on endocrine disorders, including pheochromocytoma and paraganglioma.)\n##\n(\"entity\"<|>UPTODATE INC.<|>ORGANIZATION<|>UpToDate Inc. is a clinical decision support resource that provides literature reviews and guidelines on various medical topics, including pheochromocytoma.)\n##\n(\"entity\"<|>HARRISON PRINCIPIOS DE MEDICINA INTERNA<|>ORGANIZATION<|>Harrison's Principles of Internal Medicine is a comprehensive medical textbook that includes information on pheochromocytoma.)\n##\n(\"entity\"<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>ORGANIZATION<|>Williams Textbook of Endocrinology is a key reference in the field of endocrinology, covering various endocrine disorders including pheochromocytoma.)\n##\n(\"relationship\"<|>DÍAZ PÉREZ JA<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Díaz Pérez JA is one of the authors of the Manual de Endocrinología y Nutrición, which discusses pheochromocytoma and paraganglioma<|>7)\n##\n(\"relationship\"<|>CRESPO HERNÁNDEZ I<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Crespo Hernández I is one of the authors of the Manual de Endocrinología y Nutrición, which discusses pheochromocytoma and paraganglioma<|>7)\n##\n(\"relationship\"<|>FEOCROMOCITOMA<|>PARAGANGLIOMA<|>Feochromocytoma and paraganglioma are both types of tumors that secrete catecholamines and have similar diagnostic and treatment considerations<|>8)\n##\n(\"relationship\"<|>UPTODATE INC.<|>FEOCROMOCITOMA<|>UpToDate Inc. provides clinical guidelines and literature reviews on pheochromocytoma<|>6)\n##\n(\"relationship\"<|>HARRISON PRINCIPIOS DE MEDICINA INTERNA<|>FEOCROMOCITOMA<|>Harrison's Principles of Internal Medicine includes information on pheochromocytoma<|>5)\n##\n(\"relationship\"<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>FEOCROMOCITOMA<|>Williams Textbook of Endocrinology covers pheochromocytoma among other endocrine disorders<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: , respectivamente, son malignos. La gammagrafía con 123I-metayodobencilguanidina (MIBG) ha de-\n\n## 26 En relación con el diagnóstico de feocromocitoma, indique cuál de las siguientes afirmaciones es verdadera:\n\nA. Existen numerosas medicaciones, como los antidepresivos tricíclicos o los bloqueantes de los canales de calcio, que pueden interferir en la captación de la metayodobencilguanidina (MIBG).\nB. La determinación de cromogranina A tiene una alta especificidad diagnóstica.\nC. La insuficiencia renal, aunque sea avanzada, no interfiere en la determinación de catecolaminas plasmáticas.\nD. La determinación de catecolaminas plasmáticas ofrece mayor fiabilidad diagnóstica que la determinación de metanefrinas en orina de 24 horas.\n\n### COMENTARIO\n\nDada la mayor sensibilidad de las metanefrinas en plasma pero, al mismo tiempo, un mayor riesgo de falsos positivos, esta determinación suele realizarse en primer lugar en pacientes con un riesgo alto de enfermedad (formas familiares), mientras que en pacientes con un riesgo menor suele realizarse en primer lugar la determinación de catecolaminas y metanefrinas fraccionadas en orina de 24 horas. Siempre debe recordarse que la presencia de enfermedad renal crónica avanzada invalida el resultado de las catecolaminas y metanefrinas fraccionadas en orina de 24 horas. La determinación de cromogranina A tiene una especificidad demasiado baja.\n\nAproximadamente, el 10% y el 25% de feocromocitomas y de paragangliomas, respectivamente, son malignos. La metayodobencilguanidina (MIBG) ha mostrado su utilidad diagnóstica y terapéutica en los tumores secretores de catecolaminas debido a su alta afinidad y captación por las células cromafines. Su uso diagnóstico está indicado en pacientes con grandes tumores (mayores de 10 cm), sospecha de malignidad o paragangliomas (mayor riesgo de lesiones múltiples y malignidad). La captación de la MIBG puede estar disminuida en tumores necróticos y con el uso de determinadas drogas y fármacos, como los simpa-\n---\n# SUPRARRENALES 5\n\nticomimeticos, los antidepresivos tricíclicos, la cocaína, los calcioantagonistas y el labetalol, que deben ser suspendidos 2 semanas antes de la realización de la prueba.\n\nLos antagonistas del calcio mejoran la resistencia vascular periférica al producir vasodi-latación arterial. Su papel principal es suplementar el tratamiento alfa y betabloqueante cuando el control de la presión arterial es inadecuado o reemplazarlos si se producen efec-tos secundarios intolerables (hipotensión ortostática grave tras el uso de alfabloqueantes).\n\nReferencias:\n- Díaz Pérez JA, Crespo Hernández I. Feocromocitoma y paraganglioma. Manual de Endocrinología y Nutrición. Disponible en: https://manual.seen.es (última modificación: 24 de noviembre de 2015).\n- Lenders JWM, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SKG, Murad MH, et al. Pheochromocytoma and paraganglioma: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99:1915-41.\n- Neumann HPH. Feocromocitoma. En: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscazo J, eds. Harrison Principios de Medicina Interna. 19.ª edición en español. México DF: Mc Graw Hill; 2016. p. 2329-35.\n- Young WF, Jr. Clinical presentation and diagnosis of pheochromocytoma. UpToDate. Waltham, MA: UpToDate Inc. https://www. uptodate.com. Literature review current through: Apr. 2019.\n- Young WF, Jr. Endocrine Hypertension. En: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016. p. 556-88.\n- Young WF, Jr, Kebebew E. Treatment of pheochromocytoma in adults. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate. com. Literature review current through: Apr. 2019.\n\n## 27 En relación con el manejo preoperatorio de los feocromocitomas, indique cuál de las siguientes afirmaciones es correcta:\n\nA. Pacientes normotensos y asintomáticos no precisan preparación farmacológica.\nB. La preparación farmacológica debe iniciarse el día anterior a la intervención quirúrgica.\nC. El bloqueo betaadrenérg\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}